Laurus Labs Ltd - 540222 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for New World Fund, Inc. Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Laurus Labs Limited Q1 FY-23 Earnings Conference Call Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Q1 FY23 Results conference call hosted on July 28, 2022 Laurus Labs Q1 net up 4 per cent at 251 crore
Revenue increases 20 per cent to 1,539 crore Q1FY23 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals firm Laurus Labs Announced Q1FY23 Result : Revenue at Rs 1,539 crs, up 20% (YoY) EBITDA Rs 454 crs, increased by 14% (YoY) EBITDA margins at 29.5% PAT at Rs 251 crs, increased by 4% (YoY) PAT margins at 16.3% EPS (Diluted) for the period at Rs 4.7 per share (not annualised) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Laurus Lab's performance in the first quarter of the current financial year reflects our efforts towards strengthening and diversifying our business by an increased focus on Non-ARV APIs and Formulations and high-growth CDMO segments. This strong momentum has been delivered because of our efforts toward a sustainable supply chain, capacity creation, and on-time delivery of products during the current challenging environment. Pricing pressure in ARV APIs and the Formulation business was significant during this quarter, and ARV FDF volumes would increase in the coming quarters. The high-margin CDMO business growth helped the organization deliver very good revenue and profit. Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; “In Q1 FY23, Laurus Lab has continued its strong performance with 20% revenue growth to Rs 1,539 crs, driven by solid growth in our CDMO-Synthesis business. EBITDA came at Rs 454 crs with consistent EBITDA margins of 29.5% as better mix more than offset for depressed pricing in ARV business. Our ROCE on annualised basis stood healthy ~29.4% with comfortable Balance sheet position. In Q1, Laurus Lab invested a total of Rs 209 crs Capex and we are on track to execute on our future capex schedule”. Result PDF Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed the Press Release on the financial results for the quatter ended June 30, 2022. Please take the information on record. Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the presentation to the Investors/ Analysts on the Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2022, for the Investors/Analysts call scheduled on July 28, 2022, which was already intimated on July 21, 2022. Laurus Labs Ltd - 540222 - Approval Of Un-Audited Financial Results For The Quarter Ended June 30, 2022
Approval of un-audited Financial results for the Quarter ended June 30, 2022 Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q1 FY 23 Investors call on July 28, 2022 at 11.00 AM Laurus Labs Ltd - 540222 - Board Meeting Intimation for Approval Of The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2022.
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, July 27, 2022, inter-alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2022.